Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6882
Source ID: NCT01007097
Associated Drug: Tak-875
Title: Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: TAK-875|DRUG: TAK-875|DRUG: TAK-875|DRUG: TAK-875|DRUG: TAK-875|DRUG: Glimepiride|DRUG: Placebo
Outcome Measures: Primary: Change from Baseline in Glycosylated Hemoglobin at Week 12., Baseline and Week 12 | Secondary: Change from Baseline in Fasting Plasma Glucose at Week 12., Baseline and Week 12|Change from Baseline in Body Weight at Week 12., Baseline and Week 12|Incidence of Hypoglycemia During Double-Blind Treatment Period., Per Occurrence (up to 12 weeks)
Sponsor/Collaborators: Sponsor: Takeda
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 426
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2009-12
Completion Date: 2010-09
Results First Posted:
Last Update Posted: 2016-04-13
Locations: Birmingham, Alabama, United States|Hoover, Alabama, United States|Tucson, Arizona, United States|Anaheim, California, United States|Burlingame, California, United States|Chula Vista, California, United States|Fresno, California, United States|Los Angeles, California, United States|Los Gatos, California, United States|Norwalk, California, United States|Orange, California, United States|Colorado Springs, Colorado, United States|Pueblo, Colorado, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Hialeah, Florida, United States|Jupiter, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Panama City, Florida, United States|Pembroke Pines, Florida, United States|Tampa, Florida, United States|Sandy Springs, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|La Grange, Illinois, United States|Sunset, Louisiana, United States|Portland, Maine, United States|Parkville, Maryland, United States|Rockville, Maryland, United States|Southfield, Michigan, United States|Olive Branch, Mississippi, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Camden, New Jersey, United States|West Seneca, New York, United States|Asheboro, North Carolina, United States|Burlington, North Carolina, United States|Charlotte, North Carolina, United States|Morehead City, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Carlisle, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Perrysburg, Ohio, United States|Norman, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Altoona, Pennsylvania, United States|Tipton, Pennsylvania, United States|Cranston, Rhode Island, United States|Peak, South Carolina, United States|Taylors, South Carolina, United States|Varnville, South Carolina, United States|Corpus Christi, Texas, United States|Hurst, Texas, United States|North Richland Hills, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Draper, Utah, United States|Salt Lake City, Utah, United States|Spokane, Washington, United States|Guatemala, Guatemala|Mexico City, Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Zapopan, Jalisco, Mexico|Cuernavaca, Morelos, Mexico|Monterrey, Nuevo Leon, Mexico|Tampico, Tamaulipas, Mexico
URL: https://clinicaltrials.gov/show/NCT01007097

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D482 Aliskiren small molecule DB09026 Details